European Archives - Page 251 of 1509 - European Medical Journal

EACS 2025: Once-Weekly HIV Pill Maintains Viral Suppression for 96 Weeks

New EACS data show once-weekly islatravir and lenacapavir maintain HIV viral suppression for 96 weeks with no resistance or major side effects.

Higher Cardiometabolic Risk Increases Gastrointestinal Bleeding in Aspirin Users

Higher Cardiometabolic Risk Increases Gastrointestinal Bleeding in Aspirin Users

A UK Biobank study finds aspirin users with multiple cardiometabolic risk factors—such as diabetes and hypertension—have nearly double the risk of GI bleeding.

Inside the rise of HCP podcast engagement

HCP podcast engagement is growing fast. Explore EMJ data on audience trends, popular topics and how pharma can harness this powerful channel.

Skin Cancer Detection Improved for Transplant Recipients

Skin Cancer Detection Improved for Transplant Recipients

A risk-stratified approach significantly enhanced skin cancer detection after organ transplantation without increasing health care burden.

EMJ Microbiology & Infectious Diseases 6 [Supplement 3] 2025

In August 2025, EMJ conducted individual interviews with two European medical experts and a patient advocate who…

Optimising Prostate Biopsy Strategies for TZ Tumours

The present study explored whether enhancing sampling density in the TZ could improve cancer detection.

Timely Prevention of Adolescent Invasive Meningococcal Disease

In August 2025, EMJ conducted individual interviews with two European medical experts and a patient advocate who…

Donanemab Trial Offers Hope for Alzheimer’s Treatment

New analysis reveals a link between posttreatment amyloid levels and clinical improvement in Alzheimer’s treatment outcomes.

Untangling Chronic Urticaria: Martin Metz

For me, there are two main takeaways from the study. The first is that we still don’t take CSU seriously enough. It is a debilitating…

Pectin Prebiotics Show Promise for Food Allergy Treatment

The study found that pectin treatment improved Pru p 3 tolerance in over half of participants, with 30% achieving full tolerance to the equivalent of a whole peach.